|
1
|
Ding Y, Shimada Y, Kano M, et al:
PTEN/MMAC1 expression in esophageal squamous cell carcinomas. Int J
Oncol. 17:695–699. 2000.PubMed/NCBI
|
|
2
|
Roncalli M, Bosari S, Marchetti A, et al:
Cell cycle-related gene abnormalities and product expression in
esophageal carcinoma. Lab Invest. 78:1049–1057. 1998.PubMed/NCBI
|
|
3
|
Shimada Y, Sato F, Watanabe G, et al: Loss
of fragile histidine triad gene expression is associated with
progression of esophageal squamous cell carcinoma, but not with the
patient’s prognosis and smoking history. Cancer. 89:5–11. 2000.
|
|
4
|
Tanaka H, Shimada Y, Harada H, et al:
Methylation of the 5′ CpG island of the FHIT gene is closely
associated with transcriptional inactivation in esophageal squamous
cell carcinomas. Cancer Res. 58:3429–3434. 1998.
|
|
5
|
Privette LM and Petty EM: CHFR: A novel
mitotic checkpoint protein and regulator of tumorigenesis. Transl
Oncol. 1:57–64. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hartwell LH and Weinert TA: Checkpoints:
controls that ensure the order of cell cycle events. Science.
246:629–634. 1989. View Article : Google Scholar
|
|
7
|
Hartwell LH and Kastan MB: Cell cycle
control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scolnick DM and Halazonetis TD: Chfr
defines a mitotic stress checkpoint that delays entry into
metaphase. Nature. 406:430–435. 2000. View
Article : Google Scholar
|
|
9
|
Bertholon J, Wang Q, Falette N, et al:
Chfr inactivation is not associated to chromosomal instability in
colon cancers. Oncogene. 22:8956–8960. 2003. View Article : Google Scholar
|
|
10
|
Soutto M, Peng D, Razvi M, et al:
Epigenetic and genetic silencing of CHFR in esophageal
adenocarcinomas. Cancer. 116:4033–4042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morioka Y, Hibi K, Sakai M, et al:
Aberrant methylation of the CHFR gene in digestive tract cancer.
Anticancer Res. 26:1791–1795. 2006.PubMed/NCBI
|
|
12
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
|
|
13
|
Eads CA, Lord RV, Wickramasinghe K, et al:
Epigenetic patterns in the progression of esophageal
adenocarcinoma. Cancer Res. 61:3410–3418. 2001.PubMed/NCBI
|
|
14
|
Nie Y, Yang G, Song Y, et al: DNA
hypermethylation is a mechanism for loss of expression of the HLA
class I genes in human esophageal squamous cell carcinomas.
Carcinogenesis. 22:1615–1623. 2001. View Article : Google Scholar
|
|
15
|
Momparler RL and Bovenzi V: DNA
methylation and cancer. J Cell Physiol. 183:145–154. 2000.
View Article : Google Scholar
|
|
16
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: a novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Esteller M, Sanchez-Cespedes M, Rosell R,
Sidransky D, Baylin SB and Herman JG: Detection of aberrant
promoter hypermethylation of tumor suppressor genes in serum DNA
from non-small cell lung cancer patients. Cancer Res. 59:67–70.
1999.
|
|
18
|
Chaturvedi P, Sudakin V, Bobiak ML, et al:
Chfr regulates a mitotic stress pathway through its RING-finger
domain with ubiquitin ligase activity. Cancer Res. 62:1797–1801.
2002.
|
|
19
|
Ahel I, Ahel D, Matsusaka T, et al:
Poly(ADP-ribose)-binding zinc finger motifs in DNA
repair/checkpoint proteins. Nature. 451:81–85. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oh YM, Kwon YE, Kim JM, et al: Chfr is
linked to tumour metastasis through the downregulation of HDAC1.
Nat Cell Biol. 11:295–302. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu X, Minter-Dykhouse K, Malureanu L, et
al: Chfr is required for tumor suppression and Aurora A regulation.
Nat Genet. 37:401–406. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kashima L, Toyota M, Mita H, et al: CHFR,
a potential tumor suppressor, downregulates interleukin-8 through
the inhibition of NF-kappaB. Oncogene. 28:2643–2653. 2009.
View Article : Google Scholar
|
|
23
|
Sanbhnani S and Yeong FM: CHFR: a key
checkpoint component implicated in a wide range of cancers. Cell
Mol Life Sci. 69:1669–1687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Toyota M, Itoh F and Imai K: DNA
methylation and gastrointestinal malignancies: functional
consequences and clinical implications. J Gastroenterol.
35:727–734. 2000. View Article : Google Scholar
|
|
25
|
Jones PA and Laird PW: Cancer epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mizuno K, Osada H, Konishi H, et al:
Aberrant hypermethylation of the CHFR prophase checkpoint gene in
human lung cancers. Oncogene. 21:2328–2333. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shibata Y, Haruki N, Kuwabara Y, et al:
Chfr expression is downregulated by CpG island hypermethylation in
esophageal cancer. Carcinogenesis. 23:1695–1699. 2002. View Article : Google Scholar
|
|
28
|
Fang MZ, Jin Z, Wang Y, et al: Promoter
hypermethylation and inactivation of O6-methylguanine-DNA
methyltransferase in esophageal squamous cell carcinomas and its
reactivation in cell lines. Int J Oncol. 26:615–622.
2005.PubMed/NCBI
|
